Expert Financial Analysis and Reporting

Investment Perspective With the failure of its biotechnology drug candidate aclerastide, Derma Sciences is abandoning drug development efforts. The Company has also signaled that it will slowly be phasing out of its Traditional Would Care (TWC) business which is based on commodity products including compression products, adhesive strips, impregnated dressings, wound closure and gauze. It […]